VYNE Therapeutics (VYNE) to Release Quarterly Earnings on Thursday

VYNE Therapeutics (NASDAQ:VYNE) is expected to be announcing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $0.20 million for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 15, 2026 at 12:30 PM ET.

VYNE Therapeutics (NASDAQ:VYNE) last released its quarterly earnings data on Friday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter. The business had revenue of $0.13 million during the quarter. VYNE Therapeutics had a negative net margin of 4,646.14% and a negative return on equity of 74.86%.

VYNE Therapeutics Stock Up 2.3%

NASDAQ:VYNE opened at $0.66 on Tuesday. The stock’s 50 day moving average price is $0.61 and its two-hundred day moving average price is $0.52. The firm has a market capitalization of $21.86 million, a price-to-earnings ratio of -0.84 and a beta of 2.00. VYNE Therapeutics has a 12-month low of $0.28 and a 12-month high of $1.96.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on VYNE shares. Wall Street Zen upgraded VYNE Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of VYNE Therapeutics in a research note on Wednesday, January 21st. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, VYNE Therapeutics presently has an average rating of “Reduce”.

Institutional Investors Weigh In On VYNE Therapeutics

Large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new stake in VYNE Therapeutics during the fourth quarter worth approximately $46,000. Two Sigma Investments LP acquired a new stake in VYNE Therapeutics during the third quarter worth approximately $74,000. Geode Capital Management LLC boosted its holdings in shares of VYNE Therapeutics by 64.2% in the 4th quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock valued at $131,000 after purchasing an additional 88,030 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of VYNE Therapeutics in the 4th quarter valued at $147,000. Finally, Shay Capital LLC acquired a new stake in shares of VYNE Therapeutics in the 3rd quarter valued at $165,000. Institutional investors and hedge funds own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.